Madrigal Pharmaceuticals Inc
MDGL
Get informed when a big investor buys or sells
+ FollowMarket Cap$11.78B
Close$
$1232.16
139.1% upside
Current Fair Value
139.1% upsideUndervalued by 139.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $11.78 Billion |
|---|---|
| Enterprise Value | $11.84 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-12.85 |
| Beta | -1.06 |
| Outstanding Shares | 29,145,271 |
Return
| Return on Equity | -62.07% |
|---|---|
| Return on Assets | -26.12% |
| Return on Invested Capital | -39.96% |
Valuation & Multiples
| P/E Ratio | -39.57 |
|---|---|
| PEG | -106.85 |
| Price to Sales | 11.71 |
| Price to Book Ratio | 30.31 |
| Enterprise Value to Revenue | 9.22 |
| Enterprise Value to EBIT | -34.04 |
| Enterprise Value to Net Income | -37 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | 0.66 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 4, 2026
EPS Estimate
$-2.66
Average shareholder expectationRevenue Estimate
$350.85 M
Average shareholder expectationNext Earnings Call
Expected Date
November 3, 2026
EPS Estimate
$-0.91
Average shareholder expectationRevenue Estimate
$404.19 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.9424▲ 40.53% |
|---|---|
| Total Calls | 19,100▼ 97.01% |
| Total Puts | 18,000▼ 94.76% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 10.26%▼ 95.71% |
|---|---|
| Total Invested | $1.60B▼ 87.16% |
| Investors Holding | 162▼ 244.00% |
ESG Score
No data
About Madrigal Pharmaceuticals Inc
CEO: Rebecca Taub